Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.
We have used derivatized antisense oligodeoxynucleotides both in vitro and in vivo specifically to inhibit translation of the activated human oncogene Ha-ras. The oligonucleotides (5'-CCACACCGA-3') were targeted to a region of Ha-ras mRNA including the point mutation G----T at the 12th codon which leads to a Gly----Val substitution in the ras p21 protein. They were linked to an intercalating agent and/or to a hydrophobic tail, both to increase their affinity for their mRNA target and to enhance their uptake by tumor cells. A cell-free translation system was used to demonstrate an RNase H-dependent specific inhibition of activated ras protein synthesis. 50% inhibition was observed at a concentration of 0.5 microM of the most efficient oligonucleotide (5'-substitution with an acridine derivative and 3'-substitution by a dodecanol chain). This inhibitory effect stems from a point mutation-sensitive cleavage of the mRNA and it mirrors the growth inhibition obtained with T24 bladder carcinoma cells, which carry activated Ha-ras. The proliferation of HBL100 cells (non tumorigenic human mammary cell line) which carry two copies of normal Ha-ras was unaffected. This study shows that it is possible to design antisense agents that will inactivate the mutated oncogene but not the protooncogene which is generally essential to cell survival.
Saison-Behmoaras
T
T
Laboratoire de Biophysique, INSERM U.201-CNRS UA.481, Muséum National d'Histoire Naturelle, Paris, France.
Tocqué
B
B
Rey
I
I
Chassignol
M
M
Thuong
N T
NT
Hélène
C
C
D000818:Animals; D001483:Base Sequence; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D004722:Endoribonucleases / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras; D006801:Humans; D006868:Hydrolysis; D008969:Molecular Sequence Data; D009154:Mutation; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D016283:Proto-Oncogene Proteins p21(ras) / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000737:chemistry*; D011817:Rabbits; D051381:Rats; D012156:Reticulocytes / Q000187:drug effects / Q000378:metabolism; D016914:Ribonuclease H; D012995:Solubility; D014908:Triticum / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D004722:Endoribonucleases; D016914:Ribonuclease H; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)